FibroGen First Quarter 2025 Earnings: Beats Expectations

FibroGen (NASDAQ:FGEN) First Quarter 2025 Results

Key Financial Results

• Net loss: US$16.8m (loss narrowed by 49% from 1Q 2024).
• US$0.17 loss per share (improved from US$0.33 loss in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

FibroGen Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 8.0% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for FibroGen (3 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.